Global Atopic Dermatitis (Atopic Eczema) Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

November 2017 | 189 pages | ID: G6597CF85ECEN
Precision Business Insights (PBI)

Abstracts

Atopic dermatitis is also known as atopic eczema. Atopic dermatitis is a type of inflammatory disease which is of unknown origin usually starts in early infancy, but also affects a major number of adults. Atopic dermatitis results in itchy, red, swollen and cracked skin. Many people with atopic dermatitis may develop hay fever and asthma. The causes are unknown but it is found to involve inherited, immune system dysfunction, environmental exposure and difficulties in permeability of skin. Multiple factors such as seasonal allergies, low humidity, exposure to harsh detergents & soaps, and cold weather can trigger or worsen atopic dermatitis, including. The atopic dermatitis treatment includes mainly steroid creams and moisturizers. Often, antibiotics are used when there is a skin infection. Diagnosis is done by physical examination and in some cases, biopsy is performed. Treatment aims to control inflammation and relieving itching.

Global atopic dermatitis treatment market is driven by increased R&D funding to develop biologics and development of targeted therapies for atopic dermatitis. In addition increased incidence of atopic dermatitis, new product launches, and increased awareness about the symptoms of atopic dermatitis expected to further boost the atopic dermatitis treatment market. However, availability of the generic drugs and high cost of dermatology drugs are expected to hamper the atopic dermatitis treatment market during the forecast period.

Atopic dermatitis treatment market has been segmented on the basis of drug type, route of administration and distribution channel

Based on drug type, atopic dermatitis treatment market is segmented into

• Corticosteroids
• Calcineurin Inhibitors
• Immunosuppressants
• Phosphodiesterase type 4 (PDE-4) inhibitor
• Antibiotics
• Antihistamines
• Emollients

Based on route of administration, atopic dermatitis treatment market is segmented into

• Oral
• Topical
• Parenteral

Based on distribution channel, atopic dermatitis treatment market is segmented into

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Atopic dermatitis treatment market expected to grow at steady state during the forecast period. Market players are focusing on research and development to discover new drugs to treat atopic dermatitis. Several global and regional players competing for the market share. Companies adopting several strategies such as acquisitions, mergers and partnering with other players to withstand the competition and grow their market share. For instance, AstraZeneca has entered into an agreement with LEO Pharma A/S, for the global license to tralokinumab in skin diseases. Tralokinumab is a potential new medicine that is being developed in phase II clinical trials for the treatment of patients with atopic dermatitis. In December 2016, Novartis acquired UK based Ziarco Group and expanded its R&D portfolio with once daily oral H4 receptor agonist, ZPL389, that is being developed for the treatment of atopic dermatitis. In addition, new classes of products are launched targeting atopic dermatitis other than the traditional classes such as corticosteroids. This gives the health care professionals to choose various alternatives. For instance, in February 2017, Pfizer got FDA approval for Eucris, a non-steroidal topical phosphodiesterase-4 inhibitor that is used for treatment of mild to moderate atopic dermatitis.

Geographically atopic dermatitis treatment market has been segmented into following regions Viz. North America, Latin America, Asia-Pacific, Europe, and Middle East &Africa. North America dominates atopic dermatitis treatment market, expected to show notable growth rates owing to product launches, lifestyle changes, and early treatment adoption. According to the national eczema association in the U.S., 31.6 million people are living with eczema. Europe atopic dermatitis treatment due to large research and development activities. The Asia Pacific market is expected to grow at a higher rate owing to rapid population growth, availability of large patient pool and changing lifestyle.

Some of the market players in atopic dermatitis treatment market include Leo Pharma A/S (Denmark), Velite Pharmaceutical (India), Nestlé S.A. (Galderma SA) (Switzerland), Pfizer Inc. (U.S.), Anacor Pharmaceutical Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S), Sanofi S.A. (France), Novartis AG (Switzerland), Bayer AG (Germany), Mylan N.V. (Meda Pharmaceuticals) (U.S.), Bristol-Myers Squibb (BMS) (U.S), and Allergan Plc. (Ireland) to name a few.

In March 2017, Dupixent(dupilumab), the first and only biologic medicine for the treatment of adults with moderate-to-severe atopic dermatitis, approved by U.S. Food and Drug Administration (FDA). This drug was developed by Sanofi and Regeneron Pharmaceuticals in collaboration.

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET INTRODUCTION

2.1. Global Atopic Dermatitis Treatment Market– Taxonomy
2.2. Global Atopic Dermatitis Treatment Market–Definitions
  2.2.1. Drug Type
  2.2.2. Route of Administration

3. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Atopic Dermatitis Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Atopic Dermatitis Treatment Market– Recent Market Introductions

4. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Corticosteroids
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Calcineurin Inhibitors
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Immunosuppressants
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Antibiotics
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Antihistamines
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis
5.7. Emollients
  5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.7.3. Market Opportunity Analysis

6. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Oral
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Topical
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Parenteral
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.1.1. Corticosteroids
    9.1.1.2. Calcineurin Inhibitors
    9.1.1.3. Immunosuppressants
    9.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
    9.1.1.5. Antibiotics
    9.1.1.6. Antihistamines
    9.1.1.7. Emollients
  9.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Oral
    9.1.2.2. Topical
    9.1.2.3. Parenteral
  9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Hospital Pharmacies
    9.1.3.2. Retail Pharmacies
    9.1.3.3. Online Pharmacies
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
  9.1.6. North America Atopic Dermatitis Treatment Market Dynamics – Trends

10. EUROPE ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.1.1. Corticosteroids
    10.1.1.2. Calcineurin Inhibitors
    10.1.1.3. Immunosuppressants
    10.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
    10.1.1.5. Antibiotics
    10.1.1.6. Antihistamines
    10.1.1.7. Emollients
  10.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Oral
    10.1.2.2. Topical
    10.1.2.3. Parenteral
  10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Hospital Pharmacies
    10.1.3.2. Retail Pharmacies
    10.1.3.3. Online Pharmacies
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
  10.1.6. Europe Atopic Dermatitis Treatment Market Dynamics – Trends

11. ASIA-PACIFIC ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.1.1. Corticosteroids
    11.1.1.2. Calcineurin Inhibitors
    11.1.1.3. Immunosuppressants
    11.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
    11.1.1.5. Antibiotics
    11.1.1.6. Antihistamines
    11.1.1.7. Emollients
  11.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Oral
    11.1.2.2. Topical
    11.1.2.3. Parenteral
  11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Hospital Pharmacies
    11.1.3.2. Retail Pharmacies
    11.1.3.3. Online Pharmacies
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
  11.1.6. Asia-Pacific Atopic Dermatitis Treatment Market Dynamics – Trends

12. LATIN AMERICA ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.1.1. Corticosteroids
    12.1.1.2. Calcineurin Inhibitors
    12.1.1.3. Immunosuppressants
    12.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
    12.1.1.5. Antibiotics
    12.1.1.6. Antihistamines
    12.1.1.7. Emollients
  12.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Oral
    12.1.2.2. Topical
    12.1.2.3. Parenteral
  12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Hospital Pharmacies
    12.1.3.2. Retail Pharmacies
    12.1.3.3. Online Pharmacies
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
  12.1.6. Latin America Atopic Dermatitis Treatment Market Dynamics – Trends

13. MIDDLE EAST & AFRICA ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.1.1. Corticosteroids
    13.1.1.2. Calcineurin Inhibitors
    13.1.1.3. Immunosuppressants
    13.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
    13.1.1.5. Antibiotics
    13.1.1.6. Antihistamines
    13.1.1.7. Emollients
  13.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Oral
    13.1.2.2. Topical
    13.1.2.3. Parenteral
  13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Hospital Pharmacies
    13.1.3.2. Retail Pharmacies
    13.1.3.3. Online Pharmacies
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
  13.1.6. MEA Atopic Dermatitis Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Leo Pharma A/S (Denmark)
  14.2.2. Nestlé S.A. (Galderma SA) (Switzerland)
  14.2.3. Pfizer Inc. (U.S.)
  14.2.4. Anacor Pharmaceutical Inc. (U.S.)
  14.2.5. Regeneron Pharmaceuticals, Inc. (U.S)
  14.2.6. Sanofi S.A. (France)
  14.2.7. Novartis AG (Switzerland)
  14.2.8. Bayer AG (Germany)
  14.2.9. Mylan N.V. (Meda Pharmaceuticals) (U.S.)
  14.2.10. Bristol-Myers Squibb (BMS) (U.S)
  14.2.11. Allergan Plc. (Ireland)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS